BEMS Reports, 2026; 12(2):47-52.
https://www.bemsreports.org

Brief Report

How Data and AI Can Optimise Pharmaceutical Supply Chains

Arun HS Kumar*

Stemcology, School of Veterinary Medicine, University College Dublin, Belfield, Dublin-04, IRELAND.

Correspondence:
Dr. Arun HS Kumar, DVM, PhD.,
Room 216, Stemcology, School of Veterinary Medicine, University College Dublin, Belfield, Dublin-04, IRELAND.
Email: arun.kumar@ucd.ie

Received: 14-02-2026;
Revised: 27-02-2026;
Accepted: 01-03-2026.

ABSTRACT

Pharmaceutical supply chains are highly complex, global, and tightly regulated systems that are increasingly exposed to disruption from geopolitical instability, pandemics, and demand volatility. This report examines how data and Artificial Intelligence (AI) can optimise pharmaceutical supply chains by improving forecasting accuracy, manufacturing efficiency, inventory management, logistics, quality assurance, and regulatory compliance. It argues that the industry is transitioning from isolated AI pilots toward integrated, intelligent, and potentially autonomous supply chain systems underpinned by data-driven decision-making, digital twins, and agentic AI. The report highlights the foundational role of data, emphasising that its value depends on contextualisation, integration, and governance across fragmented systems. AI applications such as machine learning-based demand forecasting, predictive inventory optimisation, and real-time analytics enable more responsive and efficient supply chain operations. In manufacturing, digital twins and predictive maintenance systems improve yield, reduce downtime, and enhance quality consistency, while AI-enabled logistics and warehouse optimisation strengthen cold-chain integrity and distribution efficiency. The report also explores AI applications in quality management and regulatory compliance, including anomaly detection, computer vision inspection, and automated documentation aligned with Good Manufacturing Practice (GMP) standards. Major technology providers such as IBM, SAP, Siemens, Microsoft, and GE Digital are enabling these capabilities through advanced industrial AI platforms. Finally, the report considers the emerging potential of agentic AI to enable autonomous decision-making across end-to-end supply chains, while recognising persistent challenges related to data quality, regulatory constraints, cybersecurity risks, and organisational readiness. Overall, the findings suggest that AI has the potential to transform pharmaceutical supply chains into more resilient, adaptive, and patient-centric systems, provided that technological innovation is matched with robust governance and organisational change.

Keywords: Agentic AI, Artificial Intelligence, Digital twins, Pharmaceutical Supply Chains, Predictive Analytics.

INTRODUCTION

Pharmaceutical supply chains are among the most complex and highly regulated operational networks in the world.[1,2] They involve global sourcing of raw materials, strict manufacturing requirements, cold-chain logistics, regulatory oversight, demand uncertainty, and the need to ensure continuous patient access to medicines. In recent years, disruptions caused by the COVID-19 pandemic, geopolitical instability, inflation, and shortages of critical medicines have highlighted vulnerabilities across the sector. As a result, pharmaceutical companies are increasingly turning to data analytics, Artificial Intelligence (AI), and digital technologies to improve supply chain resilience, efficiency, and responsiveness.[3,4] The pharmaceutical industry is moving beyond isolated AI pilots towards the development of intelligent and autonomous supply chain systems.[2,5] AI should not simply improve existing processes incrementally but should fundamentally transform how pharmaceutical supply chains operate. The emphasis is on ethical autonomous decision networks, digital twins, agile operating models, and predictive decision-making as this reflects broader developments in industry and academic literature surrounding data-driven supply chain transformation.[6-8] This report outlines how data and AI can optimise pharmaceutical supply chains by improving forecasting, manufacturing, inventory management, logistics, quality assurance, and decision-making. It also explores the organisational, ethical, and regulatory challenges associated with AI adoption and evaluates the transformational potential of agentic AI within the pharmaceutical sector.

DOI: 10.5530/bems.12.2.9

THE IMPORTANCE OF DATA IN PHARMACEUTICAL SUPPLY CHAINS

Data is the foundation of modern supply chain optimisation. Pharmaceutical companies generate enormous quantities of operational data from manufacturing systems, Enterprise Resource Planning (ERP) platforms, warehouse sensors, transportation systems, clinical trials, suppliers, and market demand signals.[9,10] Historically, much of this data existed in silos and was underutilised. However, advances in cloud computing, Internet of Things (IoT) technologies, and AI have enabled organisations to integrate and analyse these datasets more effectively. Data plays a critical role in optimising pharmaceutical supply chains by supporting a wide range of operational and strategic objectives.[4,11,12] Through the effective collection, integration, and analysis of data, pharmaceutical companies can improve demand forecasting accuracy, helping to reduce stockouts and medicine shortages while ensuring continuous patient access to treatments. Data-driven insights also enhance manufacturing efficiency by identifying process improvements and reducing operational waste. In addition, advanced analytics can improve supply chain visibility across sourcing, production, warehousing, and distribution networks, enabling organisations to respond more effectively to disruptions and changing market conditions.[4,10,11,13] Data is equally important for supporting regulatory compliance, maintaining product quality, and ensuring patient safety through continuous monitoring and traceability. Further, AI-powered data systems enable faster, more informed decision-making by providing real-time insights and predictive capabilities across the entire supply chain. Pharmaceutical companies possess "tons of data," but much of it lacks context or integration.[11,13] Raw data alone has limited value unless it is contextualised and transformed into actionable insights. This reflects findings in the wider literature, which emphasise that data governance, interoperability, and quality management are essential prerequisites for successful AI deployment.[1,2,6] The concept of data-contextualisation is particularly important in pharmaceuticals because operational decisions often depend on combining multiple data sources.[14,15] For example, manufacturing optimisation may require integrating process conditions, environmental variables, machine performance data, and quality outcomes. Without contextual integration, AI models may produce unreliable or misleading outputs.

AI APPLICATIONS IN PHARMACEUTICAL SUPPLY CHAINS

One of the most valuable applications of AI in pharmaceutical supply chains is demand forecasting. Traditional forecasting methods often struggle with sudden demand fluctuations, seasonal variation, changing disease patterns, and external disruptions.[4,16,17] AI systems can analyse historical sales data, epidemiological trends, prescribing patterns, weather conditions, and market intelligence to generate more accurate predictions. Machine learning algorithms can continuously update forecasts in real time as new information becomes available.[17-19] Improved forecasting reduces both excess inventory and stock shortages, helping companies' lower storage costs while ensuring medicine availability for patients. Inventory optimisation is particularly important in pharmaceuticals because many products have limited shelf lives and strict storage requirements. AI-driven inventory systems can dynamically balance inventory levels across distribution networks, reducing waste from expired products while maintaining service levels. Predictive analytics also allows companies to identify potential shortages earlier and proactively adjust procurement or manufacturing plans. During the COVID-19 pandemic, organisations that adopted advanced forecasting technologies were often better able to respond to disruptions in supply and demand.[17-19]Several advanced tools are currently available, or can be further developed, to support AI-driven demand forecasting and inventory optimisation in pharmaceutical supply chains.[4,20] Enterprise platforms such as SAP Integrated Business Planning (IBP), Oracle Supply Chain Management Cloud, and Kinaxis Rapid-Response already use machine learning algorithms to analyse large datasets and generate real-time demand forecasts. These systems can integrate historical sales data, hospital prescribing trends, epidemiological reports, weather patterns, and market intelligence to improve forecasting accuracy and responsiveness. In addition, AI-powered predictive analytics tools can be developed to identify potential medicine shortages before they occur, allowing organisations to proactively adjust procurement, manufacturing schedules, or distribution strategies. Digital twin technology can also simulate supply chain scenarios and assess the impact of disruptions such as pandemics, supplier failures, or transportation delays.[1,2] Internet of Things (IoT) sensors combined with AI platforms can further optimise inventory management by monitoring stock levels, environmental conditions, and product shelf life in real time, particularly for temperature-sensitive medicines and vaccines. Future developments may include autonomous inventory management systems capable of continuously balancing stock across global distribution networks with minimal human intervention, helping pharmaceutical companies reduce waste, lower operational costs, and ensure reliable patient access to medicines.

Manufacturing optimisation and digital twins process is a compelling example of achieving improved manufacturing yield. A digital twin is a virtual representation of a physical process, system, or facility that enables simulation, monitoring, and optimisation in real time. In pharmaceutical manufacturing, digital twins can replicate production processes using historical and live operational data.[8,21,22] AI models can then simulate different production conditions, identify inefficiencies, and recommend process adjustments to improve yield, quality, or energy efficiency. Some pharmaceutical organisations are reportedly using large-scale manufacturing and process data to develop an AI-driven model capable of improving production efficiency within only 90 to 100 days.[23,24] This demonstrates how agile AI implementation can generate measurable operational benefits rapidly when combined with clear accountability and focused objectives.[1,19] The academic and industry literature increasingly supports the use of digital twins in pharmaceutical manufacturing due to their ability to improve operational performance and process control.[8,21,22] Digital twins can help reduce production variability by continuously monitoring and simulating manufacturing conditions, allowing organisations to identify inefficiencies and optimise processes more quickly. This leads to lower material waste, improved product quality consistency, and reduced equipment downtime, all of which contribute to greater manufacturing efficiency and cost savings. In addition, digital twins can accelerate the scale-up of new products by enabling manufacturers to test and refine production processes virtually before full implementation. These technologies are particularly valuable in biologics manufacturing, where production processes are highly complex, sensitive, and difficult to manage using traditional manufacturing methods alone.AI and simulation technologies can also optimise warehousing and distribution operations. Digital simulation model have been used to validate a warehouse environment without relying solely on traditional thermal mapping techniques.[1,25] By integrating warehouse design, HVAC systems, material flow, and environmental conditions, the company identified weaknesses before the warehouse became operational. This example highlights how AI can support predictive infrastructure validation and regulatory compliance. Pharmaceutical warehouses require strict temperature and humidity control, especially for vaccines and biologics. AI-enabled environmental monitoring systems can continuously assess conditions and predict risks before deviations occur. In logistics, AI can optimise transportation routes, reduce delivery times, and improve cold-chain monitoring. Machine learning systems can analyse traffic data, weather conditions, shipment histories, and transport performance to identify the most efficient delivery strategies.[17,18] IoT sensors integrated with AI platforms can monitor temperature-sensitive shipments in real time, reducing the risk of product degradation during transit. If temperature deviations occur, automated alerts can trigger corrective actions immediately.Manufacturing interruptions caused by equipment failures can significantly disrupt pharmaceutical supply chains. AI-powered predictive maintenance systems use sensor data and machine learning algorithms to detect early signs of equipment degradation before breakdowns occur. By monitoring vibration, pressure, temperature, and operational patterns, AI models can predict maintenance requirements more accurately than traditional scheduled maintenance programmes.[26,27] This reduces downtime, extends equipment life, and improves production continuity. Predictive maintenance is especially important in pharmaceutical manufacturing because equipment failures may result in batch losses, contamination risks, or regulatory compliance issues. Several technology enterprises currently provide AI-powered predictive maintenance tools that can support pharmaceutical manufacturing and supply chain resilience. Companies such as IBM, Siemens, GE Digital, SAP, Microsoft, and Schneider Electric offer industrial AI and Internet of Things (IoT) platforms capable of monitoring equipment performance in real time. For example, IBM Maximo Application Suite uses machine learning and advanced analytics to predict equipment failures and optimise maintenance scheduling, while Siemens MindSphere and GE Digital's Predix platform analyse sensor data from manufacturing equipment to detect abnormal operating conditions before breakdowns occur.[28,29] Microsoft Azure IoT and SAP Predictive Asset Insights also enable pharmaceutical manufacturers to integrate machine data, environmental monitoring, and operational analytics into centralised AI systems. These platforms continuously monitor variables such as vibration, pressure, temperature, humidity, and operational cycles to identify early signs of equipment degradation. By predicting maintenance needs more accurately than traditional time-based servicing programmes, these technologies help reduce unplanned downtime, extend equipment lifespan, improve production continuity, and minimise the risk of batch losses or contamination. In highly regulated pharmaceutical environments, predictive maintenance tools also support compliance by improving process reliability, traceability, and quality assurance across manufacturing operations.AI has growing applications in pharmaceutical quality management and regulatory compliance. Machine learning algorithms can analyse production data to identify anomalies, detect deviations, and predict quality issues before they affect final products. Computer vision systems powered by AI are increasingly used in visual inspection processes to identify packaging defects, contamination, or labelling errors more consistently than human inspectors. Regulatory compliance is another important area.[4,30] Pharmaceutical manufacturing is governed by strict Good Manufacturing Practice (GMP) requirements. AI systems can help automate documentation, monitor compliance metrics, and support audit readiness. Interestingly even regulators are increasingly willing to learn alongside industry as AI technologies mature. This reflects broader regulatory developments, including growing interest in AI governance frameworks, explainable AI, and validation standards for machine learning systems in regulated environments. A growing number of AI-powered tools are now available to support pharmaceutical quality management and regulatory compliance, with major technology and industrial automation companies playing a leading role in this area. Organisations such as IBM, SAP, Siemens, Honeywell, Microsoft, and ABB offer AI-enabled platforms designed to improve manufacturing quality control, process monitoring, and GMP compliance.[31,32] Solutions such as SAP Quality Management, Siemens Opcenter, IBM Watsonx, and Honeywell Forge use machine learning algorithms to analyse production and operational data in real time, helping manufacturers detect anomalies, identify deviations, and predict quality issues before they impact final pharmaceutical products. In addition, AI-powered computer vision systems from companies such as Cognex and Keyence are increasingly used for automated visual inspection processes, enabling more accurate detection of packaging defects, contamination, fill-level inconsistencies, or labelling errors compared to manual inspection methods.[33,34] These technologies also support regulatory compliance by automating documentation workflows, monitoring compliance metrics, maintaining audit trails, and improving traceability across manufacturing operations. As regulatory agencies become more open to AI adoption, there is growing industry focus on explainable AI, validation frameworks, and AI governance standards to ensure that machine learning systems remain transparent, reliable, and compliant within highly regulated pharmaceutical environments.

The agentic AI and autonomous decision networks are also conceptually evolving. Unlike conventional automation systems that follow predefined rules, agentic AI refers to systems capable of making adaptive decisions, learning from data, and coordinating actions across interconnected processes.[35,36] In supply chains, agentic AI could enable autonomous coordination between procurement, manufacturing, warehousing, transportation, and inventory systems. For example, if a disruption occurs at a supplier facility, AI systems could automatically evaluate alternative sourcing options, adjust production schedules, reroute shipments, and notify relevant stakeholders. This represents a shift from reactive supply chain management towards predictive and self-optimising networks.[37,38] Pharmaceutical supply chains increasingly require continuous monitoring and rapid decision-making to respond to disruptions, shortages, and changing market conditions. Agentic AI has the potential to transform pharmaceutical supply chains by enabling more intelligent, adaptive, and autonomous operational capabilities.[35,36] These systems could support real-time operational optimisation by continuously analysing data across manufacturing, logistics, procurement, and distribution networks to improve efficiency and responsiveness. Agentic AI may also enable autonomous risk mitigation by identifying potential disruptions, shortages, or equipment failures early and automatically recommending or initiating corrective actions. In addition, AI-driven systems could support dynamic production scheduling, continuous scenario modelling, and faster responses to unexpected events such as supply chain disruptions or sudden changes in demand.[35,36] Another major advantage is the ability to provide end-to-end supply chain visibility, allowing organisations to monitor products, inventory, and operational performance across global networks in real time. However, despite these advancements, fully autonomous pharmaceutical supply chains remain a long-term ambition rather than a present-day reality. Human oversight continues to be essential, particularly within highly regulated pharmaceutical environments where accountability, regulatory compliance, product quality, and patient safety remain critical priorities.

Organisational and Cultural Transformation

Successful AI adoption depends as much on organisational culture as on technology itself. Many AI initiatives fail not because of technical limitations but because organisations struggle to adapt operating models, leadership structures, and employee capabilities. Companies seeking rapid AI transformation should avoid traditional programme management approaches and instead adopt agile operating models with smaller autonomous teams, which emphasises cross-functional collaboration, decentralised decision-making, and rapid iteration.[20,39] Agile methodologies are particularly valuable for AI projects because machine learning development is iterative and experimental. Teams need flexibility to test models, refine algorithms, and adapt quickly to changing operational requirements. Change management is also essential. Employees may resist AI adoption due to concerns about job displacement, trust in automated systems, or uncertainty regarding new processes. Organisations must therefore invest in communication, training, and workforce development to build confidence and support adoption.

The pharmaceutical industry also faces a significant digital skills gap.[40] Effective AI implementation requires expertise in data science, machine learning, cloud computing, process engineering, and regulatory compliance. Companies must therefore invest heavily in talent development and interdisciplinary collaboration. Despite its significant potential, the adoption of AI in pharmaceutical supply chains is accompanied by several important challenges and risks that must be carefully managed.[1,19] One of the primary issues is data quality and integration, as AI systems are highly dependent on accurate, complete, and well-structured data; however, in many pharmaceutical organisations, data remains fragmented across legacy systems, suppliers, and different business functions, with inconsistent formats, missing values, and limited interoperability, all of which can undermine model performance and reliability. Regulatory and ethical concerns also present major barriers, given that pharmaceutical operations are strictly governed to ensure patient safety, meaning that any AI system used in manufacturing, quality management, or decision-making must meet rigorous validation, transparency, and compliance requirements, while also addressing risks such as algorithmic bias, accountability, and explainability in automated decisions.[2,4] In addition, cybersecurity risks are becoming increasingly significant as supply chains become more digitalised and interconnected, exposing AI-enabled systems to potential cyberattacks, ransomware, and data breaches across global networks.[41,42] Finally, implementation costs remain a considerable challenge, as deploying AI solutions requires substantial investment in data infrastructure, cloud computing, sensors, specialised software, and skilled personnel, which can make large-scale adoption particularly difficult for smaller pharmaceutical companies.

FUTURE OUTLOOK

The future pharmaceutical supply chain is likely to become increasingly intelligent, interconnected, and predictive. Emerging technologies such as generative AI, edge computing, blockchain, and advanced robotics will further enhance supply chain automation and visibility. In the coming years, pharmaceutical companies may move towards "self-healing" supply chains capable of detecting disruptions and autonomously implementing corrective actions. AI agents could coordinate supplier networks, optimise production globally, and continuously adjust logistics operations in response to changing conditions. Digital twins may also expand beyond individual facilities to model entire end-to-end supply chains, enabling organisations to simulate geopolitical disruptions, pandemics, or supplier failures before they occur. However, technological advancement alone will not guarantee success. Organisations must simultaneously invest in governance, ethics, workforce development, and agile operating cultures. Data and AI have the potential to fundamentally transform pharmaceutical supply chains by improving forecasting accuracy, manufacturing efficiency, inventory optimisation, logistics management, quality assurance, and decision-making.

CONCLUSION

In conclusion, AI can deliver measurable operational improvements while supporting regulatory compliance and patient outcomes. More broadly, the emergence of agentic AI and autonomous decision networks signals a shift towards predictive and self-optimising supply chains capable of responding dynamically to disruption and uncertainty. Nevertheless, successful AI transformation requires more than technological implementation. Organisations must address data quality, regulatory requirements, cybersecurity risks, workforce capabilities, and cultural resistance to change. The central question facing pharmaceutical companies is not whether they want to improve existing systems incrementally, but whether they are prepared to fundamentally transform how supply chains operate. Ultimately, the pharmaceutical companies that successfully integrate data, AI, and agile operating models will likely achieve significant competitive advantages through greater resilience, efficiency, responsiveness, and patient-centricity in an increasingly complex global environment.

ABBREVIATIONS

AI: Artificial Intelligence; **GMP:** Good Manufacturing Practice; **ERP:** Enterprise Resource Planning; **IoT:** Internet of Things; **IBP:** Integrated Business Planning; **HVAC:** Heating, Ventilation, and Air Conditioning; **ML:** Machine Learning; **PSC:** Pharmaceutical Supply Chain; **CNN:** Convolutional Neural Network; **LSTM:** Long Short-Term Memory; **IT:** Information Technology; **PLC:** Programmable Logic Controller.

CONFLICT OF INTEREST

The author declares that there is no conflict of interest.

REFERENCES

1. Vadaga AK, Dokuburra UR, Nekkanti H, Gudla SS, Kumari RK. Digital transformation in pharmaceuticals: The impact of AI on supply chain management. Intelligent Hospital. 2025;1:1-15.
2. Majumdar K, Jain J, Mohan D. AI-Driven Optimization of Pharmaceutical Supply Chains: Enhancing Forecasting, Inventory, and Transparency. Springer; 2025.
3. Prajapati M. We are integrating artificial intelligence and data analytics for supply chain optimization in the pharmaceutical industry. J Electrical Systems. 2024;20:682-90.
4. Nguyen A, Lamouri S, Pellerin R, Tamayo S, Lekens B. Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges. International Journal of Production Research. 2022;60:6888-907.
5. Yogeswaran P, Singh RK, Modgil S. Supply chain 4.0 technologies for value creation in pharmaceutical industry. Journal of Global Operations and Strategic Sourcing. 2025;18:585-606.
6. Park KM, Pattnaik S, Liew N, Kundu T, Kures AO, Pinsky E. Smarter chains, safer medicines: From predictive failures to algorithmic fixes in global pharmaceutical logistics. Forecasting. 2025;7:78.
7. Chava K, Kanthety SS. Emerging applications of generative AI and deep neural networks in modern pharmaceutical supply chains: a focus on automated insights and decision-making. South Eastern European Journal of Public Health. 2024;24:20-45.
8. Celestin M. How digital twins are enhancing supply chain resilience against market disruptions. Brainae Journal of Business, Sciences and Technology (BJBST). 2023;7:989-99.
9. Mhaskey SV. Optimizing healthcare distribution: The role of enterprise resource planning systems. Int J Multidiscip Res Growth Eval. 2025;6:1809-13.
10. Kumar G. Advancements in Pharmaceutical IT: Transforming the Industry with ERP Systems. Pharmacology. 2025;4:13-9.
11. Kutybayeva K, Razaque A, Rai HM. Enhancing Pharmaceutical Supply Chain Transparency and Security with Blockchain and Big Data Integration. Procedia Computer Science. 2025;259:1511-22.
12. Ziaee M, Shee HK, Sohal A. Big data analytics in Australian pharmaceutical supply chain. Industrial Management and Data Systems. 2023;123:1310-35.
13. Wanjekeche JN, Machoka P. Supply chain visibility and performance of pharmaceutical distribution firms in nairobi city county, kenya. International Journal of Innovation, Enterprise, and Social Sciences. 2025;5:228-45.
14. Oluwagbade E, Vincent A, Oluwole O, Blessing A. Lifecycle governance for explainable AI in pharmaceutical supply chains: a framework for continuous validation, bias auditing, and equitable healthcare delivery. Int J Eng Technol Res Manag. 2023;7:54.
15. Ahlqvist V, Dube N, Jahre M, Lee JS, Melaku T, Moe AF, *et al.* Supply chain risk management strategies in normal and abnormal times: policymakers' role in reducing generic medicine shortages. International Journal of Physical Distribution and Logistics Management. 2023;53:206-30.
16. Priyadharshini P, Keerthana S, Devi GK. Optimizing Pharmaceutical Supply Chains using a Hybrid CNN-LSTM Model for Accurate Medicine Demand Forecasting. Paper/Poster presented at: 2025 3rd International Conference on Self Sustainable Artificial Intelligence Systems (ICSSAS); 2025.
17. Yani LPE, Aamer A. Demand forecasting accuracy in the pharmaceutical supply chain: a machine learning approach. International journal of pharmaceutical and healthcare marketing. 2023;17:1-23.
18. Joshi SV, Patil SB, Patil SN, Bhosle S, Karhadkar NP, Rathore YK. Machine learning applications in hospital pharmacy for predicting drug shortages and supply chain optimization. Research Journal of Pharmacy and Technology. 2025;18:2739-45.
19. Al-Hourani S, Weraikat D. A systematic review of Artificial Intelligence (AI) and Machine Learning (ML) in Pharmaceutical Supply Chain (PSC) resilience: Current trends and future directions. Sustainability. 2025;17:6591.
20. Abedi S, Kwon S, Yoon SW. Healthcare and pharmaceutical supply chain automation. In: Springer handbook of automation. Springer;2023: 1289-308.
21. Khan S. Real-time health supply chain optimization using digital twin technology. International Journal of Science and Research Archive. 2025;15:1275-89.
22. Burattini S, Montagna S, Gentili N, Galardi F, Vespignani R, Zanatto P, *et al.* A digital twins approach for oncologic pharmaceutical supply chain. Paper/Poster presented at: 2024 IEEE International Conference on Pervasive Computing and Communications Workshops and other Affiliated Events (PerCom Workshops); 2024;

23. Takechi K. Negative effects of intellectual property protection on entry into foreign markets: Internal versus external supply decisions by large Japanese and US pharmaceutical firms. The International Economy. 2024;27:41-51.
24. Volgina NA. Business models of big pharma in Russia: A pharmaceutical value chain perspective. RUDN Journal of Economics. 2022;30:57-69.
25. Bayrami A, Shahriari MR, Lotfi FH. The Analysis of Scenario Simulations of Smart Pharmaceutical Distribution Model in the Pharmaceutical Supply Chain Industry. Journal of Resource Management and Decision Engineering. 2024;3:151-68.
26. Shashikumar N. Predictive maintenance and inventory optimization in medical device supply chains: a data-driven approach. Network Modeling Analysis in Health Informatics and Bioinformatics. 2025;15:4.
27. Oluwole O, Emmanuel E, Ogbuagu OO, Alemede V, Adefolaju I. Pharmaceutical supply chain optimization through predictive analytics and value-based healthcare economics frameworks. International Journal of Engineering Technology Research and Management. 2024;8:88-104.
28. Soundararajan G, Virmani D, Sharma P, Tewari PC, Kuzieva N, Gurusamy M. Supply Chain Innovations in Automotive Risk Assessment With AI Algorithms. In: AI's Role in Enhanced Automotive Safety. IGI Global Scientific Publishing; 2025: 469-82.
29. Patel NR. Supply chain management in the digital age for industry 4.0. In: Industry 4.0, smart manufacturing, and industrial engineering. CRC Press; 2024: 179-95.
30. Glaser AE, Harrison JP, Josephs D. Anomaly detection methods to improve supply chain data quality and operations. SMU Data Science Review. 2022;6:3.
31. Saini JPS, Thakur A, Yadav D. AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations. RSC Pharmaceutics. 2025;2:437-54.
32. Saha GC, Eni LN, Saha H, Parida PK, Rathinavelu R, Jain SK, *et al.* Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making. Rivista Italiana di Filosofia Analitica Junior. 2023;14:2023.
33. Maślanka M, Jancarczyk D, Rysinski J. Integration of Machine Vision and PLC-Based Control for Scalable Quality Inspection in Industry 4.0. Sensors. 2025;25:6383.
34. Jancarczyk D, Rysiński J, Worek J. Comparative Analysis of Measurement Tools in the Cognex D900 Vision System. Applied Sciences. 2024;14:8296.
35. Reddy CKK, Joseph S, Joshi H, Doss S, Ouaissa M. The Power of Agentic AI: Redefining Human Life and Decision-Making. In Industry 6.0. Switzerland: Springer Nature Switzerland; 2025.
36. Pamisetty A. Application of agentic artificial intelligence in autonomous decision making across food supply chains. European Data Science Journal. 2024;1:1-15.
37. Ghobakhloo M, Okwir S, Iranmanesh M, Fathi M, Foroughi B. Artificial intelligence-enabled antifragility in production and supply chain operations. Production Planning and Control. 2026: 1-21.
38. Fatorachian H, Kazemi H. Optimizing supply chains with AI: a systematic review through the lens of systems theory. Cogent Engineering. 2026;13:2639206.
39. Ajayi-Kaffi O, Emmanuel I, Azonuche TI, Ijiga OM. Agile-Driven Digital Transformation Frameworks for Optimizing Cloud-Based Healthcare Supply Chain Management Systems. International Journal of Scientific Research and Modern Technology. 2025;4:138-56.
40. Bakare RT, Koshechkin K, Tariq M, Saleha Q. Communication Technologies: Bridging Gaps in Pharmaceutical Industry Connectivity-Review of Digital Pharma Innovation. Journal of Epidemiology and Public Health. 2025;3:1-8.
41. Solfa FDG. Impacts of cybersecurity and supply chain risk on digital operations: evidence from the pharmaceutical industry. International Journal of Technology Innovation and Management (IJTIM). 2022;2:18-32.
42. Del Giorgio Solfa F. Impacts of cyber security and supply chain risk on digital operations. International Journal of Technology, Innovation and Management. 2022;2:18-32.

Cite this article: Kumar AHS. How Data and AI Can Optimise Pharmaceutical Supply Chains. BEMS Reports. 2026;12(2):47-52.